When Roche's division for early research and development enters into new partnerships, this is oftentimes a way of getting new technologies on board – be they new types of immunotherapy, gene therapy or new RNA technologies.
William Pao, who heads Roche's division for early research and development – Pharma Research and Early Development (pRED) – would like to see Roche engage more in such activities.
Already a subscriber? Log in.
Read the whole article
Get 14 days free access.
No credit card required.
Get full access for you and your coworkers.Start a free company trial today
Your trial for MedWatch has now started
With your free trial you get:
Full access to all locked articles on MedWatch.
Daily newsletter and ongoing top-newsletters. You can unsubscribe and subscribe to our newsletters anytime.
When your trial period expires
You will not be transferred to a paid subscription.
You will continue to receive our newsletters after the trial period expires. You can unsubscribe at the bottom of each newsletter.